Connect Biopharma Holdings Limited Basic Shares Outstanding (Weighted Average)
Connect Biopharma Holdings Limited (CNTB) reported Basic Shares Outstanding (Weighted Average) of 62.88 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-12
- Connect Biopharma Holdings Limited weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 62.88M shares, a 13.31% increase year-over-year.
- Connect Biopharma Holdings Limited weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 56.55M shares, a 2.16% increase year-over-year.
- Connect Biopharma Holdings Limited weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 56.07M shares, a 1.38% increase year-over-year.
- Connect Biopharma Holdings Limited weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 55.72M shares, a 0.84% increase year-over-year.
- Connect Biopharma Holdings Limited weighted average number of shares outstanding, basic for fiscal 2025 was 55.66M shares, a 0.81% increase from fiscal 2024.
- Connect Biopharma Holdings Limited weighted average number of shares outstanding, basic for fiscal 2024 was 55.21M shares, a 0.27% increase from fiscal 2023.
- Connect Biopharma Holdings Limited weighted average number of shares outstanding, basic for fiscal 2023 was 55.07M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 62.88M shares 10-Q · filed 2026-08-12 | 59.73M shares 10-Q · filed 2026-08-12 | 58.50M shares derived: average of 3 quarters · filed 2026-08-12 | 57.80M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 56.55M shares 10-Q · filed 2026-05-12 | 56.31M shares derived: average of 2 quarters · filed 2026-05-12 | 56.11M shares derived: average of 3 quarters · filed 2026-05-12 | 55.96M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | 56.07M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 55.89M shares derived: average of 2 quarters · filed 2026-03-31 | 55.76M shares derived: average of 3 quarters · filed 2026-08-12 | 55.66M shares 10-K · filed 2026-03-31 |
| 2025-09-30 | 55.72M shares 10-Q · filed 2025-11-12 | 55.61M shares derived: average of 2 quarters · filed 2026-08-12 | 55.52M shares 10-Q · filed 2025-11-12 | 55.47M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | 55.50M shares 10-Q · filed 2026-08-12 | 55.43M shares 10-Q · filed 2026-08-12 | 55.39M shares derived: average of 3 quarters · filed 2026-08-12 | 55.35M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | 55.35M shares 10-Q · filed 2026-05-12 | 55.33M shares derived: average of 2 quarters · filed 2026-05-12 | 55.30M shares derived: average of 3 quarters · filed 2026-05-12 | 55.28M shares derived: average of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | 55.31M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 55.28M shares derived: average of 2 quarters · filed 2026-03-31 | 55.25M shares derived: average of 3 quarters · filed 2026-03-31 | 55.21M shares 10-K · filed 2026-03-31 |
| 2024-09-30 | 55.25M shares 10-Q · filed 2025-11-12 | 55.22M shares derived: average of 2 quarters · filed 2025-11-12 | 55.18M shares 10-Q · filed 2025-11-12 | |
| 2024-06-30 | 55.19M shares 10-Q · filed 2025-08-13 | 55.15M shares 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | 55.10M shares 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | 55.07M shares 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |